- Human genetics pioneer at Cambridge University joining Adrestia to discover and validate new synthetic rescue targets for intractable genetic diseases
- Large-scale human population analysis will help identify and validate the safety and efficacy of new targets emerging from the Companys platform
- Human genetics enriches Adrestias Synthetic Rescue Atlas, helping to inform indication expansion from gateway genetic diseases into more prevalent diseases with a shared genetic component
- Human genetic validation builds conviction in the Companys portfolio of first-in-class therapies to treat neurologic, neuromuscular and cardiomyopathic diseases
CAMBRIDGE, England(BUSINESS WIRE)May 18, 2022
Professor John R.B. Perry, a world-renowned human population genetics researcher at the University of Cambridge, has been named vice president of Human Genetics. He has previously developed a series of first-in-class therapies to treat both rare and common diseases with a genetic component.
This press release is available in full format: https://www.businesswire.com/news/home/20220518005013/en/.
Vice President of Human Genetics, Professor John R.B. Perry (Photo: Business Wire)
Dr Perry believes that within the 8 billion living humans, each single base substitution in the genome that is compatible with life is likely to be present somewhere. This genetic diversity is developed by a hypothesis-free population wide screen for identifying and validating genes that have triggered or influenced human disease. Dr Perry is adamant to develop these innovative methods to help better understand other countries'' problems effectively.
Professor Perry has been involved in establishing several of the first genetic factors of various diseases, including obesity, Type 2 diabetes, reproductive disorders, and behaviors. His work to better understand the genetic architecture of disease will enable greater drug target selection and the formulation of more predictive models of disease, both resulting in increased drug development success rates. These are key areas in his professional development at Adrestia, where he has worked to develop more effectively.
Despite advances in genetic technologies, many genes that directly cause disease remain unruggable. Synthetic rescue offers a fresh approach: rather than targeting the causative mutation, a synthetic rescue drug modulates the product of another functionally connected gene, correcting the effects of the disease mutation and rescuing cells from disease. The therapeutic potential of the synthetic rescue is shown in families where a member born with a disease-causing mutation is protected from disease due to a second rescue mutation. Synthetic rescue offers new opportunities for drug development
The aim of our synthetic rescue tool, supplemented with John''s human genetics expertise, is to create a new paradigm, where success chances are significantly higher, the production cost is significantly reduced, and the time to establish clinical proof of concept is substantially shorter. John is in a position to aspire to develop revolutionary new medicines for people who suffer from devastating diseases.
Dr Perry, a researcher and professor of Molecular Endocrinology at the University of Cambridge, has served as an Associate Group Leader at The University of Cambridge, as well as as as a Fellow and Director of Studies at Kings College Cambridge. While serving at Adrestia, he will continue in these roles.
Dr Perry was a visiting researcher at the University of Exeter Medical School, the Wellcome Trust Centre for Human Genetics at the University of Oxford, and the Department of Twin Research at Kings College London, and the Center for Statistical Genetics at the University of Michigan. He has published over 150 books in peer reviewed journals, many of which include Nature, Science, Nature Genetics, and computer science.
Adrestias'' synthetic rescue platform
Adrestia has developed a powerful synthetic rescue drug development platform that has already identified completely new approaches to treating intractable genetic diseases. Each component is designed to provide robust validation of new druggable abilities and develop a synthetic rescue Atlas of the human genome. As the Atlas expands, the possibilities to utilize synthetic rescue medicines to treat both rare and common diseases are continuing.
This powerful platform, built on decades of research undertaken by Professor Steve Jacksons laboratory at the University of Cambridge, in synthetic rescue and the related notion of synthetic lethality for cancer treatment. The Jackson Laboratorys work has provided a slew of concepts, techniques, and expertise, which has now been translated into the Adrestias platform.
Adrestia: What Happened?
Adrestia''s platform and in-house programs are complemented by a target discovery partnership with GSK and a Huntingtons disease collaboration with prominent researchers.
Adrestia was co-founded by Professor Steve Jackson and the deep technology investment firm Ahren Innovation Capital, who coordinated Adrestias Series A financing with GSK. Jackson co-originated the first synthetic lethality drug, olaparib, which was the first drug known to treat cancers caused by inherited mutations. For more information, please visit: http://www.adrestia.com.
On businesswire.com, visit the source page: https://www.businesswire.com/news/home/20220518005013/en/.